Chimeric antigen receptor gene-modified lymphocyte having cytocidal effect
AssigneesShinshu University, Kyoto Prefectural Public University Corporation
InventorsHajime Hosoi, Tomoko Iehara, Shigeki Yagyu, Yozo Nakazawa
Life of this patent
Estimating the term…
Abstract
An object of the present invention is to provide a therapeutic strategy in the solid tumor area and a method and a composition useful therefor to further advance the clinical application of CAR therapy. There is prepared a gene-modified lymphocyte which expresses a chimeric antigen receptor having an EphrinB2 extracellular domain at the antigen recognition site.
Claims3
A chimeric antigen receptor comprising an extracellular domain including an EphrinB2 extracellular domain, a transmembrane domain, and an intracellular signal domain for the effector function of immunocytes, wherein the chimeric antigen receptor is encoded by the polynucleotide of SEQ ID NO:
- 3, and the EphrinB2 extracellular domain of the chimeric antigen receptor binds to Ephrin type-A receptor 2 (EPHA2) and Ephrin type-B receptor 4 (EPHB4).
Dependencies are inferred from the claim text.